Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metatinib Tromethamine in Advanced Solid Tumors
NCT02650375Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of metatinib in gastric cancer (GC), hepatocellular carcinoma (HCC), colorectal cancer (CRC) and 1 more (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Incidence of Adverse Events. Status: unknown.
02
Drugs
metatinib
03
Conditions
gastric cancer (GC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02650375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650375.